Working… Menu
Trial record 11 of 54 for:    acalabrutinib

An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02180724
Recruitment Status : Active, not recruiting
First Posted : July 3, 2014
Last Update Posted : February 1, 2019
Information provided by (Responsible Party):
Acerta Pharma BV

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 2018
Estimated Study Completion Date : August 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 23, 2019
October 15, 2019